Accelerate Drug Commercialization and LCM

Product launch is never the end of a drug’s story. Commercialization plans generally revolve around answering questions concerning life cycle management: what markets should we launch into next? 

What types of evidence are the reimbursement agencies looking for? What new indications should we target? What kind of research must we generate to support this claim? 

Real world data, as the mirror into how drugs are used and received in the real world, is the next frontier to generating these insights.

Find out how COTA can help accelerate commercial decisions and drive LCM strategy.

Why use Real-World Data?

At COTA, we curate regulatory-grade oncology RWD with the most relevance for our life sciences and provider partners, whether that involves supporting regulatory filings or research questions.  We cannot unlock the full value of RWD without the highest-quality collection and curation methodology, and we are powering a revolution in the development of new cancer therapies to bring clarity to cancer care.

 

How we define regulatory-grade data:

Provenance

  • COTA oversees the entire process from abstraction of raw data to final delivery of curated RWD
  • Traceability of all our data: where it originates, the transformations applied, and QA checks along the way

Relevance

  • The right cohorts after applying inclusion/exclusion criteria at the right volumes

  • Representativeness across real-world and clinical trial populations

  • Coverage across geographies of interest

Fidelity

  • Faithful representation of the original clinical data documented in EHR
  • Technology-enabled human abstraction leveraged to understand and capture clinical nuances
  • Accuracy of capture ensured through documented, multi-step QA/QC process
cotaIMG2

We have a responsibility to drive the use of RWD by consistently improving our data and demonstrating its utility. Our data has been used to support FDA and EMA submissions, explain care patterns, understand patient outcomes, and much more – and we anticipate the number of use cases to multiply in the coming years as RWD is explored and leveraged by more and more innovators in the industry.

Interested in learning more about how we can transform cancer care together?

RWD Resources

So you want to train an oncology LLM: Start by getting close to the data

To create targeted LLMs that are suitable for diving into health-related areas like oncology, we must choose our data carefully and get as close to the original source as possible to avoid “playing telephone” with inaccurate information that could affect drug development processes or cancer outcomes.

Read More
COTA wins google cloud award

COTA Wins Google Cloud Customer of the Year Award for using AI to Improve Cancer Care

A panel of senior Google Cloud executives selected COTA from a pool of entries to win *2* Google Cloud Customer Awards. These awards showcase companies from around the world who are using Google Cloud technologies to improve their operations, and their social and governance efforts.

Read More
How real-world data is enhancing our understanding of lung cancer recurrence Blog

How real-world data is enhancing our understanding of lung cancer recurrence

While the incidence of lung cancer is decreasing over time, and survival rates are on the rise year-over-year, there is still much to learn about how to best treat this disease – and prevent its recurrence after initial therapy.

Read More

Join the Conversation

Find COTA at upcoming events, and see where we’ve been.
No event found!

Past Events

06Aug

JSM 2022

Walter E. Washington Convention Center
15May

ISPOR 2022

Gaylord National Resort & Convention Center
13May

AUA 2022

New Orleans Ernest N. Morial Convention Center
No event found!
Load More

Request a Demo

  • This field is for validation purposes and should be left unchanged.

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.